Biotech
Commented by Mario Hose on April 13th, 2026 | 07:30 CEST
100% Profit Potential in Sight: Vidac Pharma's Chance to Double vs Bayer and Evotec
Even in the spring of 2026, the stock market remains highly volatile. The upheavals caused by geopolitical crises have been and remain significant and ever-present. While heavyweights like Bayer are struggling to shake off their legal baggage and Evotec is steering into calmer waters, a stock from the back row is suddenly stepping into the spotlight. Vidac Pharma has also had a few turbulent months, and this is precisely where experienced investors now sense an opportunity. With a current share price of EUR 0.56, the company is poised for a potential recovery, an uptick, and perhaps even a complete revaluation. If the strategy pays off, the EUR 1 mark could be reached. That would be a chance to double their money for bold investors. But what is behind this optimism? In this report, we take a look at the industry giants and analyze not only them but also why, of all three, the one with the smallest market capitalization could develop the greatest momentum. It is about potential breakthroughs in cancer research and a management team that is optimizing many aspects for success.
Read
Commented by Carsten Mainitz on April 10th, 2026 | 08:20 CEST
Unlocking Massive Potential in Pharma's Largest Segment: Innovator Vidac Pharma, Industry Leader Bayer, or Turnaround Candidate Evotec?
Oncology is the most strategically important growth market in the pharmaceutical industry and at the same time one of the key levers for improving global health. Currently, around 20 million people worldwide are diagnosed with cancer each year, a figure expected to exceed 30 million annually by 2040. The global oncology drug market is already valued at over USD 200 billion and continues to expand rapidly. Bayer aims to rank among the world's leading oncology players by 2030 and recently reaffirmed its medium-term targets. Following the sale of a stake in a cancer specialist, shareholders of Evotec, which has faced significant pressure, may soon benefit from a welcome inflow of funds. Vidac Pharma, on the other hand, is breaking new ground in the fight against skin cancer. There is enormous potential here.
Read
Commented by Stefan Feulner on April 2nd, 2026 | 07:05 CEST
SAP, Desert Gold, Novo Nordisk – Strong Rebound Potential
Donald Trump's surprise announcement that he intends to end the Iran conflict is sparking renewed activity in the markets. After weeks of uncertainty and, in some cases, sharp price declines, sentiment is noticeably improving. Many stocks had previously suffered from geopolitical pressure but could now be poised for a strong rebound. Investors are increasingly looking toward a possible easing of tensions, falling risk premiums, and a return of capital to riskier asset classes.
Read
Commented by Mario Hose on April 1st, 2026 | 07:00 CEST
Vonovia, Novo Nordisk, and Lahontan Gold: Choose between concrete gold, weight-loss hype, and Nevada's treasure!
The capital market in the spring of 2026 is a whirlwind of emotions. Real estate stocks are struggling to regain ground after the interest rate freeze. In the pharmaceutical sector, a Danish giant is under pressure and has made headlines. Away from the big stage, a smaller player in the mining sector is emerging, one that, after a consolidation phase, now aims to head north. In this report, we take a look at the real estate group Vonovia and the pharmaceutical weight-loss specialist Novo Nordisk. Both stocks have had turbulent months and could now begin to regain lost ground. Another focus is on Lahontan Gold. The Nevada-based company has recently made important strategic moves. Following a financing round, the stock price has stalled briefly. However, the latest exploration news suggests that the stock could now regain strong momentum.
Read
Commented by Nico Popp on March 31st, 2026 | 08:20 CEST
Dividends as Portfolio Anchors: Familiar Names Sanofi and BB Biotech – Hidden Gem RE Royalties
In a market environment marked by structural upheaval, portfolio stability is increasingly coming into focus. Analysts at JPMorgan emphasize that preserving accumulated gains requires a renewed focus on resilience and diversification. Research by S&P Global also shows that dividends have contributed over 50% to the total return of global equities over the past 25 years. Choosing the right stocks is crucial to securing steady cash flows even during volatile market phases. Pharmaceutical giant Sanofi, investment firm BB Biotech, and the virtually unknown Canadian company RE Royalties offer fundamentally different but extremely promising approaches for investors.
Read
Commented by Nico Popp on March 30th, 2026 | 08:30 CEST
A Paradigm Shift in Oncology: Core Stocks Roche & Galderma and the High-Leverage Opportunity in Vidac Pharma
Medical advances affect us all. Oncology is also undergoing a transformation. As conventional immunotherapies for skin cancer increasingly reach their limits, clinical research is shifting its focus to correcting defective tumor metabolism. The Warburg effect, where cancer cells shift energy production to aerobic glycolysis to fuel uncontrolled growth, offers a promising entry point. This dynamic development landscape is exacerbated by an impending patent cliff, which, according to calculations by the consulting firm PwC, threatens industry revenues of USD 104 billion by 2028, as many patents for active ingredients are expiring. Currently, market researchers at Fortune Business Insights estimate the volume of the global oncology market for 2026 at USD 286.36 billion. While pharmaceutical giant Roche secures its market leadership and the Galderma Group dominates standard dermatological care, biotechnology company Vidac Pharma is targeting the metabolic vulnerability of cancer cells with a completely novel mechanism of action, aiming to effectively shut down the cancer.
Read
Commented by Fabian Lorenz on March 26th, 2026 | 06:55 CET
Over 50% Upside Potential? BioNTech, TUI, and Bayer Partner MustGrow
Looking for an under-the-radar opportunity with significant upside potential? MustGrow may fit the profile. With a market capitalization of under CAD 40 million, its biological and regenerative crop protection solutions have already attracted the interest of Bayer. The Leverkusen-based company has licensed the mustard seed-based technology for Europe, Africa, and the Middle East and is investing a double-digit million amount. A full takeover is also not out of the question. Meanwhile, takeover speculation surrounding BioNTech has eased following the founders' surprise departure, and attention is slowly shifting back to the research pipeline. Analysts have confirmed their "Buy" recommendation. The same applies to TUI. The war in Iran is causing uncertainty among investors, while the company is simultaneously reporting an increase in flight capacity for the spring and summer seasons.
Read
Commented by André Will-Laudien on March 25th, 2026 | 09:35 CET
Oil Volatility Shakes Markets – Life Sciences Stocks Back in Focus: Bayer, Vidac Pharma, Valneva, Novo Nordisk, and Pfizer
The conflicts in the Middle East continue. With the first talks between the US and Iran, the stock markets made a lightning-fast upward adjustment. As a result, the German benchmark index DAX 40 gained a full 1,600 points within just 10 minutes at the start of the week. However, it was unable to hold that level, falling back to 22,600 points yesterday. The question now is whether the parties to the conflict can actually reach a viable solution. Completely unfazed by the broader market conditions, some news is making waves in the life sciences sector, driving price movements here and there. It is good to shift the focus away from daily market fluctuations and toward other profitable sectors. Here are a few ideas.
Read
Commented by Fabian Lorenz on March 20th, 2026 | 09:00 CET
Which stock to buy now? Evotec, Nel, and Lahontan Gold in focus
What is driving Nel's sudden rebound? Within just a few days, the former hydrogen hopeful has surged more than 20% in value, breaking out of its short-term downtrend. Yet analysts do not see a trend reversal. Instead, they point to a risk in the order backlog. In contrast, the gold explorer Lahontan Gold currently offers an interesting entry opportunity following a sharp correction. The company aims to expand the resource estimate of its flagship Nevada project beyond 2 million ounces. If successful, the stock could be materially undervalued. Evotec, on the other hand, continues to struggle with investor sentiment. Even a recent milestone payment failed to provide positive momentum, with the stock declining further yesterday.
Read
Commented by Armin Schulz on March 20th, 2026 | 08:35 CET
Act Now! Invest in cancer research with BioNTech, Vidac Pharma, and Pfizer and secure returns
Global healthcare spending is surging, and the oncology sector promises above-average returns. As the global population continues to age, the number of new cancer cases is expected to rise to over 30 million annually by 2040, intensifying competition among pharmaceutical companies for market share in this trillion-dollar industry. However, it is not yesterday's established drugs that offer the greatest profit potential, but rather radical technological shifts. While BioNTech is now deploying its billion-dollar mRNA platform against tumors, Vidac Pharma is pursuing an entirely novel approach aimed at starving cancer cells. At the same time, Pfizer is pushing aggressively into this field. We take a closer look at the current situation of these three companies.
Read